SCHEMBL21504255

SCHEMBL21504255

CC(C(=O)Nc1ccc(Cl)cc1)C12CC(NC(=O)OC3CC3)(C1)C2

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 16/20 0.81
▸ BCHE P06276 1/20 0.39
▸ ATF4 P18848 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24118261 0.90 IDO1 (1.00) IDO1
SCHEMBL24118471 0.85 IDO1 (1.00) IDO1
SCHEMBL21504118 0.83 IDO1 (0.60) IDO1
SCHEMBL21503953 0.79 IDO1 (0.53) IDO1BCHE
SCHEMBL21504228 0.79 IDO1 (0.63) IDO1
SCHEMBL24118079 0.75 IDO1 (1.00) IDO1
SCHEMBL21504168 0.75 IDO1 (0.58) IDO1
SCHEMBL30056253 0.74 IDO1 (1.00) IDO1
SCHEMBL21504226 0.74 IDO1 (1.00) IDO1
SCHEMBL30056397 0.74 IDO1 (1.00) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed
WO-2019204180-A1 NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 IDO1 1/4885BCHE 120/4885ATF4 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback